FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response	0.5							

	Check this box if no longer subject
	to Section 16. Form 4 or Form 5
\Box	obligations may continue. See
	Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Racine Jean-Olivier					2. Issuer Name and Ticker or Trading Symbol Outset Medical, Inc. [OM]										all app Direc	olicable) etor		erson(s) to I	wner
(Last) 3052 OR	(Fi	(First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 05/16/2023								X	belov	er (give title v) nief Techn		Other (s below) gy Officer	specify
(Street)	SE CA	A 9	95134			4. If Amendment, Date of Original Filed (Month/Day/Year)								. Indivine) X	′				
(City)	(St	ate) (2	Zip)		Rule 10b5-1(c) Transaction Indication														
							nsaction was r tions of Rule 1					truction or wr	itten p	DIAN THAT IS IN	ended to				
		Table	I - No	on-Deriva	tive S	ecui	rities	Acc	quired	, Dis	sposed of	f, or E	Benefic	ially	/ Owr	ned			
1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/V				Execut Year) if any		emed tion Date, n/Day/Year)		3. 4. Securities Acquire Disposed Of (D) (Inst S)					5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				
Common Stock 05/16/20.)23				S		735	D	\$19.9	91 ⁽¹⁾ 79,2		,227 ⁽²⁾	7 ⁽²⁾ D		
		Tab	le II	- Derivativ (e.g., pu							osed of, convertib				Owne	ed			
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, urity or Exercise (Month/Day/Year) if any			4. Transaction Code (Instr. 8)							7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4				9. Number derivative Securities Beneficially Owned Following Reported Transactio (Instr. 4)	e s S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

- 1. The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 16, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
- 2. Includes 1,422 shares of Common Stock acquired pursuant to the Outset Medical, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the purchase period of September 1, 2022 to February 28, 2023. This transaction is exempt from Rule 16b-3(c).

By: John L Brottem For:

Jean-Olivier Racine

05/16/2023

** Signature of Reporting Person Date

 $Reminder: \ Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.